185 related articles for article (PubMed ID: 31497220)
1. CD8
Peng GL; Li L; Guo YW; Yu P; Yin XJ; Wang S; Liu CP
Am J Transl Res; 2019; 11(8):5039-5053. PubMed ID: 31497220
[TBL] [Abstract][Full Text] [Related]
2. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast.
Xu Y; Lan S; Zheng Q
Tumori; 2018 Jun; 104(3):196-201. PubMed ID: 28430349
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
[TBL] [Abstract][Full Text] [Related]
5. A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis.
Papaioannou E; Sakellakis M; Melachrinou M; Tzoracoleftherakis E; Kalofonos H; Kourea E
Anticancer Res; 2019 Mar; 39(3):1217-1232. PubMed ID: 30842152
[TBL] [Abstract][Full Text] [Related]
6. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer.
Shen Z; Zhou S; Wang Y; Li RL; Zhong C; Liang C; Sun Y
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1585-95. PubMed ID: 20221835
[TBL] [Abstract][Full Text] [Related]
7. The impact of tumor-infiltrating lymphocytes on tumor features and pathological characteristics in breast cancer patients: the role of cytotoxic T lymphocytes and regulatory T cells.
Fares M; Ayoub NM; Marji R; Al Bashir SM; Al-Shari OM
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(12):4207-4219. PubMed ID: 35776019
[TBL] [Abstract][Full Text] [Related]
8. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
Gao Q; Qiu SJ; Fan J; Zhou J; Wang XY; Xiao YS; Xu Y; Li YW; Tang ZY
J Clin Oncol; 2007 Jun; 25(18):2586-93. PubMed ID: 17577038
[TBL] [Abstract][Full Text] [Related]
11. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis.
Takenaka M; Seki N; Toh U; Hattori S; Kawahara A; Yamaguchi T; Koura K; Takahashi R; Otsuka H; Takahashi H; Iwakuma N; Nakagawa S; Fujii T; Sasada T; Yamaguchi R; Yano H; Shirouzu K; Kage M
Mol Clin Oncol; 2013 Jul; 1(4):625-632. PubMed ID: 24649219
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
13. Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer.
Zhou F; Shayan G; Sun S; Huang X; Chen X; Wang K; Qu Y; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Shi X; Liu Y; Liang B; Li YX; Wang J; Yi J
Front Immunol; 2022; 13():1015283. PubMed ID: 36439177
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
[TBL] [Abstract][Full Text] [Related]
15. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.
de Jong RA; Leffers N; Boezen HM; ten Hoor KA; van der Zee AG; Hollema H; Nijman HW
Gynecol Oncol; 2009 Jul; 114(1):105-10. PubMed ID: 19411095
[TBL] [Abstract][Full Text] [Related]
16. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
17. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
[TBL] [Abstract][Full Text] [Related]
19. In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype.
Anz D; Eiber S; Scholz C; Endres S; Kirchner T; Bourquin C; Mayr D
Histopathology; 2011 Nov; 59(5):965-74. PubMed ID: 22092408
[TBL] [Abstract][Full Text] [Related]
20. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.
Horn T; Laus J; Seitz AK; Maurer T; Schmid SC; Wolf P; Haller B; Winkler M; Retz M; Nawroth R; Gschwend JE; Kübler HR; Slotta-Huspenina J
World J Urol; 2016 Feb; 34(2):181-7. PubMed ID: 26055646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
